CRYBG1 and prostate carcinoma: However, our results indicate that AIM1 is highly expressed in primary prostate cancers as well as in cultured androgen-independent prostate cancer cells, and support the potential of AIM1 inhibition in prostate cancer management, most likely in combinatorial treatment approaches.